Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
DSIP (delta sleep-inducing peptide) is an endogenous nonapeptide first isolated from rabbit brain in the late 1970s by Schoenenberger and Monnier. While its name references early electrophysiology work, a substantial and distinct body of preclinical literature examines DSIP outside of sleep, specifically as a candidate modulator of the hypothalamic-pituitary-adrenal (HPA) axis and of nociceptive (pain) signaling. In these studies the peptide is treated as a laboratory probe of neuroendocrine and sensory circuitry.
This article surveys how DSIP (15 mg) is investigated in stress-axis and pain research models. The focus here is on preclinical HPA and nociception endpoints rather than the sleep angle. Every statement below describes what DSIP is studied for in in-vitro and animal research; nothing here implies human use, dosing, or efficacy. These materials are for research use only, not for human consumption.
DSIP Identity and Molecular Profile
Before reviewing the stress and pain literature, it helps to fix the compound’s molecular identity, since consistent characterization underpins reproducible laboratory work.
Origin and Structure
DSIP is a small, linear peptide built from nine amino acid residues. Its widely cited sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (single-letter WAGGDASGE). Unlike receptor-selective analogs, DSIP is an endogenous sequence, and much of the research interest lies in mapping the pathways it appears to touch rather than a single named receptor.
Physicochemical Snapshot
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported value |
|---|---|
| Common name | Delta sleep-inducing peptide (DSIP) |
| Amino acid sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Sequence length | 9 residues (nonapeptide) |
| Approx. molecular weight | 848.8 g/mol |
| Molecular formula | C35H48N10O15 |
| Class | Endogenous neuropeptide |
Because the sequence carries acidic residues (Asp, Glu) and no cysteine, handling considerations differ from disulfide-bonded peptides. Laboratories typically confirm identity and purity against a supplier certificate of analysis before use.
DSIP and the HPA Stress Axis in Preclinical Models
A recurring theme in the DSIP literature is its relationship to the hypothalamic-pituitary-adrenal axis, the core neuroendocrine circuit that coordinates the vertebrate stress response. Rather than acting on sleep architecture, this branch of research treats DSIP as a candidate modulator of stress-hormone signaling.
Corticotropin and Glucocorticoid Signaling
Investigators have measured how experimental DSIP exposure relates to circulating corticotropin (ACTH) and glucocorticoids (corticosterone in rodents, cortisol in other species). Some animal reports describe a blunting of stress-evoked glucocorticoid surges, while others emphasize context-dependent or biphasic effects tied to timing and the specific stressor. Upstream, a subset of studies has looked at corticotropin-releasing hormone (CRH) signaling as a possible point of interaction. Because these are preclinical observations gathered across varied protocols, the data are best read as hypothesis-generating rather than settled.
Stress-Resistance and Oxidative Paradigms
DSIP has also featured in stress-resistance models, where rodents are exposed to immobilization, cold, or combined emotional and physical stressors. Endpoints in these designs include tissue markers of oxidative damage and the activity of antioxidant enzymes such as superoxide dismutase and catalase. The framing is often described as adaptogenic, meaning DSIP is examined for how it might relate to an organism’s capacity to buffer stress load under controlled conditions. This remains research use only, not for human consumption, and no clinical conclusion should be drawn from it. Researchers comparing neuropeptides in this space sometimes place DSIP alongside anxiolytic-studied sequences like Selank, which is examined in adjacent stress and anxiety paradigms.
DSIP in Preclinical Pain and Nociception Research
A separate and distinct line of investigation places DSIP within nociception research, the study of how the nervous system detects and processes noxious stimuli. This work is entirely preclinical and relies on standardized animal assays with defined, measurable outputs.
Thermal and Chemical Nociceptive Assays
Classic endpoints include the hot-plate and tail-flick tests, which quantify the latency of a reflexive response to a thermal stimulus, and chemically induced writhing assays that count nocifensive behaviors. Researchers compare response latencies or event counts between DSIP-exposed and control animals to characterize any antinociceptive signal. Reported outcomes vary with dose, administration route, and timing, so cross-study comparison requires caution.
Opioidergic and Monoaminergic Interactions
Several studies have probed whether DSIP-associated antinociception involves the endogenous opioid system, in some cases using the opioid antagonist naloxone to test whether an observed effect is reversible. Others have examined monoaminergic contributions. The mechanistic picture remains incomplete, and across this literature DSIP is handled as a research probe of pain circuitry, not as an analgesic and not for any therapeutic purpose.
Comparing the Stress-Axis and Pain Research Angles
Although the stress-axis and pain literatures both sit outside DSIP’s original sleep context, they use different models, endpoints, and signaling systems of interest. The summary below reflects commonly reported laboratory attributes and is provided for comparison only.
| Research angle | Representative preclinical models | Primary measured endpoints | Signaling systems of interest |
|---|---|---|---|
| HPA stress axis | Immobilization, cold, and emotional-physical stress in rodents | ACTH, corticosterone, CRH, oxidative and antioxidant markers | Hypothalamic-pituitary-adrenal axis |
| Nociception and pain | Hot-plate, tail-flick, chemical writhing assays | Response latency, threshold, nocifensive counts | Opioidergic and monoaminergic pathways |
Framed this way, the two angles are complementary rather than interchangeable: one asks how DSIP relates to neuroendocrine stress output, the other how it relates to sensory processing. Laboratories sourcing the peptide for either line of work can review batch certificates and browse the full research peptide catalog for related compounds.
Frequently Asked Questions
What is DSIP studied for in stress research?
In preclinical research, DSIP (delta sleep-inducing peptide) is investigated as a possible modulator of the hypothalamic-pituitary-adrenal (HPA) axis. Animal studies have examined its relationship to stress hormones such as corticotropin (ACTH) and corticosterone under experimental stress conditions. This work is exploratory and limited to laboratory models.
How does DSIP relate to the HPA axis in animal models?
Reported rodent studies have looked at whether DSIP exposure is associated with changes in HPA-axis output, including corticotropin-releasing hormone signaling and glucocorticoid levels, after stressors such as immobilization or cold exposure. The peptide is studied as a research probe of stress-axis regulation, not as a therapeutic agent.
Is DSIP investigated in pain research models?
Yes. DSIP has been examined in animal antinociception assays such as the hot-plate and tail-flick tests, where researchers measure the latency of a response to a thermal stimulus. Some studies have explored whether its effects involve opioid signaling. These are preclinical pain-model observations only.
What is the molecular weight and sequence of DSIP?
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE) and an approximate molecular weight of 848.8 g/mol. These attributes are commonly reported laboratory values provided for comparison only.
How is the stress-axis angle different from the sleep angle?
The name delta sleep-inducing peptide reflects early electrophysiology work, but the stress-axis and pain literature examines separate endpoints such as glucocorticoid output and nociceptive latency. This article focuses on those HPA and pain models rather than sleep architecture.
Is DSIP available for human use?
No. DSIP offered by Rejuven8 Peptides is for research use only, not for human consumption. It is not a drug, is not approved for therapeutic use, and is intended solely for laboratory investigation.
References and Further Reading
- PubMed: delta sleep inducing peptide isolation
- PubMed: DSIP hypothalamic pituitary adrenal
- PubMed: DSIP corticosterone stress
- PubMed: DSIP antinociception
- PubMed: DSIP opioid analgesia
- PubMed: DSIP oxidative stress
- PubMed: delta sleep inducing peptide review
